폐암 (NSCLC)

AntibodyBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4

ADCBiologicstalePfizerPhase 1

PF-08046033 (PF-08046033)

Non-Small-Cell Lung; Esophageal Cancer · Non-Small-Cell Lung

#Non-Small-CellLung#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

ADCBiologicstalePheon TherapeuticsPhase 1

PHN-010 (PHN-010)

Lung Cancer; Colon Cancer · Lung Cancer

#LungCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 DISCONTINUED

AntibodystaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3

#AdvancedorMetastaticNon-squamous#Antibody#Phase3#항체#면역항체+2

EU (Pembrolizumab, Pembrolizumab (EU))

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer · Advanced or Metastatic Non-squamous Non-

#AdvancedorMetastaticNon-squamous#Antibody#Phase3#항체#면역항체+2

US (Pembrolizumab, Pembrolizumab (US))

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer · Advanced or Metastatic Non-squamous Non-

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2

Investigator's choice (Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice))

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

임상시험 1상태 DISCONTINUED

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

효능 ORR 84%임상시험 1상태 DISCONTINUED

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab Immunotherapy)

Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer · Non-Small Cell Lung Cancer

임상시험 1상태 DISCONTINUED

#Non-small-cellLungCancer#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab and Chemotherapy drugs)

Non-small-cell Lung Cancer · Non-small-cell Lung Cancer

효능 ORR 62.1%임상시험 1상태 RECRUITING

#Melanoma#Antibody#Phase2#항체#면역항체+3

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

효능 ORR 56.3%임상시험 1상태 ACTIVE

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2

pembrolizumab (Keytruda, Pembrolizumab, Sintilimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#EGFR#Antibody#Phase2#항체#면역항체+4

pembrolizumab (Keytruda, Pembrolizumab, pemetrexed, platinum)

Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor · EGFR

AntibodystaleMerus B.V.Phase 2

pembrolizumab (Keytruda, Petosemtamab + Pembrolizumab)

Lung Cancer - Non Small Cell Squamous; Lung Cancer - Non Small Cell Non-Squamous · Lung Cancer - Non Small Cell Squamous

#LungCancer-NonSmallCellSquamous#Antibody#Phase2#항체#면역항체+3

AntibodystaleLG ChemPhase 1

atezolizumab (Tecentriq, Phase 1b: LB-LR1109 and Atezolizumab)

Non-small Cell Lung Cancer(NSCLC); Head and Neck Squamous Cell Carcinoma(HNSCC) · Non-small Cell Lung Cancer(NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase1#항체#면역항체+3

AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3

AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3

AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3

ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 1L)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2